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Abstract
Background: Systemic inflammation is present in chronic obstructive pulmonary disease (COPD). A whey
peptide-based enteral diet reduce inflammation in patients with COPD, but its effect on COPD development has
not been determined. On the other hand, it is known that short chain fatty acids (SCFAs), which are produced
by micro-flora in the gut, attenuates bronchial asthma in mice model.
Methods: Mice with elastase-induced emphysema were fed with 1 of 3 diets (control diet, whey peptide-based
enteral diet, or standard enteral diet) to determine the effects of whey peptide-based enteral diet on emphysema
and on cecal SCFAs.
Results: The whey peptide-based enteral diet group exhibited fewer emphysematous changes; significantly lower
total cell counts in bronchoalveolar lavage fluid (BALF); and significantly higher cecal SCFA levels than either the
control or standard enteral diet groups. The total cell count was inversely correlated with total cecal SCFA levels
in these three diet groups.
Conclusions: The whey peptide-based enteral diet attenuates elastase-induced emphysema through the suppression
of inflammation in the lung. This may be related to the increase in cecal SCFA.
Keywords: Elastase, Emphysema, Whey peptide, C57BL/6 mice, Chronic obstructive pulmonary disease, Short chain
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Background
Chronic obstructive pulmonary disease (COPD), which
includes emphysema and chronic bronchitis, is recog-
nized as a major public health issue [1] and involves
more than just the airway [2, 3]. Systemic inflammation
is present in all disease stages [2] and contributes to co-
morbidities such as cardiovascular disease, malnutrition,
and osteoporosis [2, 4].
A whey peptide-based enteral diet, as well as whey
protein and its hydrolysate, has demonstrated anti-
inflammatory effects in a variety of experimental ani-
mal models [5–8] and COPD patients [9]. However,
the effect of a whey peptide-based enteral diet on the
development of COPD has not been elucidated. More-
over, the mechanisms explaining how this diet sup-
presses inflammation have not been fully investigated.
Recent epidemiological studies have demonstrated that
dietary fiber intake is related to better lung function and
prevention of COPD [10–12]. Dietary fiber is delivered
intact to the large intestine and is then metabolized to
organic acids by intestinal micro-flora. A selection of short
chain fatty acids (SCFAs) present in these organic acids
provide benefits for the host [13]. Recently the SCFA has
been proved to relate with attenuation of bronchial hyper-
sensitibity in mice model [14]. We recently demonstrated
that changes in SCFA levels in the cecum of rats were
related to decreased antioxidant capacity during cigarette
smoke exposure; therefore, these changes may contribute
to the regulation of lung inflammation [15].
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The current study aimed at investigating the ability of
a whey peptide-based enteral diet to suppress elastase-
induced emphysema in mice and to alter the SCFA
levels in the cecum. Moreover in order to explore the re-
lationship between the gut environment and the lung
under instillation of elastase, the correlation between the
changes in cell counts in the lung and alteration in the
SCFA levels in elastase- instilled mice was investigated.
Methods
Animals and diets
Six-week-old, female C57BL/6 mice were purchased
from Japan SLC, Inc. (Shizuoka, Japan) for use in this
study. Animals were preconditioned with a commercial
solid diet (AIN-93G; Oriental Yeast Co., Ltd., Tokyo,
Japan) and water ad libitum for 2 weeks before instilla-
tion of elastase in the laboratory animal research center
at Nara Medical University. Following this precondition-
ing, the animals were divided into 3 groups according to
dietary composition: (1) control diet (AIN-93G; n = 4); (2)
lyophilized enteral diet, namely, a whey peptide-based en-
teral diet (MEIN®; Meiji Co., Ltd., Tokyo, Japan; n = 4);
and (3) standard enteral diet (MEIBALANCE®; Meiji Co.,
Ltd., Tokyo, Japan; n = 4) (Table 1). Each group was fed
the respective diet for the 4 weeks of the study.
The animals were kept in a limited-access barrier hous-
ing, which was maintained at room temperature (22 ±
1 °C), a humidity level of 55 ± 10 %, and a 12-h light/
dark cycle with illumination extending from 08:00 to
20:00. All procedures were carried out under the control
of our committee in accordance with The Guidelines for
Animal Experiments in the Nara Medical University
and Guiding Principles for the Care and Use of Labora-
tory Animals approved by The Japanese Pharmacological
Society.
Elastase emphysema model
We used an elastase-induced emphysema model, based
on previously published protocol [16]. After the precon-
ditioning, 1.2 UI/body porcine pancreatic elastase (PPE),
freshly prepared in phosphate buffered saline (PBS), was
administered intratracheally at 50 μL directly into the
airways under pentobarbital sodium anesthesia (Somno-
pentyl®, 50 mg/kg, i.p.; Kyoritsu Seiyaku Co., Ltd., Tokyo,
Japan). PBS-instilled mice fed with the control diet were
used as a sham [15] group.
Analyses of BALF and morphology
We analyzed BALF and morphology as previously re-
ported [16]. Four weeks after PPE instillation, the animals
received an intraperitoneal injection of pentobarbital so-
dium before euthanization. After removal of both lungs,
1 mL of sterile PBS was instilled and then collected twice
using a 1-mL syringe. The collected lavage fluid was
analyzed as BALF, and the cells were counted using a
hemocytometer. After collecting the cells supernatant of
the BALF was stored at −80 °C until measurement of
inflammatory cytokines. Cell differentials were counted
using smears prepared by Cytospin and stained with Diff-
Quik (Sysmex, Kobe, Japan). Whole lungs were inflated
with 4 % paraformaldehyde at a pressure of 25 cm H2O
and then fixed in formalin for 24 h, embedded with paraf-
fin, sectioned in the sagittal plane, and stained with
hematoxylin and eosin [16].
The mean linear intercept (MLI) as the morphologic
parameter on the lung tissues was calculated as follows,
based on previously published protocols [17]. Digital
images were captured at both 200× and 400× magnifica-
tions. Horizontal, vertical and diagonal grid lines were
overlaid and used to count the number of alveolar septa
intersections. MLI was calculated as follows: length of
grid lines divided by the number of intersections with
alveolar septa.
Detection of SCFAs in the cecal content
We measured SCFA levels in the cecum as previously
reported [18]. The ileocecal and cecocolonic junctions
were ligated, and the cecum was removed. The cecum
was immediately frozen and stored at −80 °C until fur-
ther analyses. The cecal contents were drained from the
cecocolonic junction into a 50-mL vial and then used for
analyses. SCFAs in the cecum were measured by high
performance liquid chromatography (Shimadzu, Kyoto,
Japan) with an internal standard. Approximately 100 mg
of the cecal content was homogenized using ultrasonica-
tion in 1 mL of a 10 mM sodium hydroxide aqueous
solution containing 5 mM crotonic acid as an internal
standard, and the mixture was centrifuged at 10,000 × g
for 15 min. The fat-soluble substances in the supernatant
were extracted using chloroform. The neutralization of
the cecal contents with sodium hydroxide prevented the
extraction of SCFAs and crotonic acid by the chloro-
form. The aqueous phase was then passed through a
membrane filter (cellulose acetate, 0.20 μm pore size;
DISMIC-13cp; Advantec Toyo, Tokyo, Japan). The sam-
ple was applied to a high performance liquid chroma-
tography column (Shimadzu, Kyoto, Japan) for analysis
of SCFAs.
SCFAs were measured according to the method of
Hoshi et al. [19] with a minor modification. SCFAs were
separated in an ion-exclusion column and detected by a
post-column pH-buffered electroconductivity detection
method, using a double-connected H-type cation ex-
changer column (Shim-pack SCR-102H, 8 mm i.d.
×30 cm long; Shimadzu, Tokyo, Japan), with a column
temperature of 45 °C, a mobile phase of a 5 mM p-
toluene sulfonic acid aqueous solution (0.8 mL/min flow
rate, 45 °C), an electroconductivity detector of positive
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polarity at 45 °C (type CDD-6A; Shimadzu, Tokyo,
Japan), and a detection reagent of a 20 mM bis Tris aque-
ous solution containing 5 mM p-toluene sulfonic acid and
100 μM ethylenediaminetetraacetic acid (0.8 mL/min flow
rate, 45 °C).
Each cecal SCFA level is adjusted for weight of the cecal
contents and indicated as μmol/g cecal content. The total
SCFA level was calculated as the sum of acetate, propion-
ate, n-butyrate, i-butyrate, and i-valerate.
Detection of inflammatory cytokines in serum
Blood samples were obtained from heart after euthaniza-
tion. The blood was centrifuged at 4 °C and the plasma
was collected and stored at −80 °C until measurement of
inflammatory cytokines. The inflammatory cytokines
(TNF-α and IL-6) levels in the plasma and the BALF
were determined using a mouse inflammation cytomet-
ric bead array kit (CBA; BD Biosciences, San Diego, CA,
USA). The assay sensitivity of TNF-α and IL-6 was 7 pg/
μL, and 5 pg/μL, respectively.
Relationship between total cecal SCFA content and total
cell count in the BALF from elastase-instilled mice
To investigate the relationship the gut environment and
the lung after elastase-instillation, we investigated rela-
tionship between total cecal SCFA levels and total cell
count in the BALF from elastase-instilled mice.
Statistical analysis
Comparisons between the 2 groups were conducted using
Mann–Whitney U tests. Relationship between total cecal
SCFA content and total cell count in the BALF from
elastase-instilled mice was conducted using single linear
regression analysis. A p value <0.05 was considered statis-
tically significant.
Results
Changes in body weight
Figure 1 illustrates the changes in body weight that oc-
curred over the course of the experiment. There were no
significant differences among the 4 groups in body
weight at the any week before and after elastase instilla-
tion (sham group and elastase-induced groups [control,
whey peptide-based enteral, and standard enteral diets]).







Proteins (g) 4.8 5.0 4
Proteins (%kcaI) 19 20 16
Protein Sources case in Whey peptides Milk
protein
L-cystine fermented milk Na case
inate




CHO Sources cornstarch isomaltulose dextrin
sucrose dextrin
Lipids (g) 1.9 2.8 2.8
Lipids(%kcal) 17 25 25
MCT (g) - 0.59 -
EPA,DHA (g) - 0.06 -
n-6/n3 - 2.0 3.2
Vitamins
Vitamin A (μg RE) 32 150 60
Vitamin D (μg) 0.70 0.75 0.50
Vitamin E (mg) 2.0 5.0 3.0
Vitamin K (μg) 24 3.4 3.1
Vitamin B1 (nm) 0.13 0.25 0.15
Vitamin B2 (mg) 0.16 0.30 0.20
Niacin(mg) 0.8 3.0 1.6
Vitamin B6(mg) 0.16 0.30 0.30
Vitamin B12(μg) (166 (160 (160
Folic acid (μg) 50 50 50
Biotin (μg) 5.3 7.5 15
Vitamin C (mg) - 50 16
Choline (mg) 28 9.2 1.7
Carnitine (mg) - 15 -
Minerals
Sodium(mg) 28 70 110
Potassium (mg) 80 80 100
Calcium (ne) 133 80 60
Magnesium (mg) 14 20 3)
Phosphorus (mg) 80 70 60
Iron (mg) 1.2 1.0 1.0
Zinc (mg) 1.0 1.0 0.80
Copper(mg) 0.160 0.050 0.080
Manganese (mg) 0.266 0.175 0.200
Chromium (μg) 26.6 2.96 3.00
Molybdenum (μg) 4.0 2.5 2.5
Selenium(μg) 4.8 5.0 3.5
Table 1 The composition of experimental diets (per 100 kcal)
(Continued)
Iodine (μg) 5.3 9.7 15
Chloride (mg) 43 80 140
MCT: median chain triglyceride, EPA: eicosapentaenoic acid, DHA: docosahexaenoic
acid
RE: retinol equivalent. (−): No additives
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Whey diet mitigated elastase-generated emphysema like
phenotype
The morphological differences in the lungs at the end of
the 4-week study period are illustrated in Fig. 2. In the
control diet group (Fig. 2a), the elastase instillation in-
duced emphysematous lesions with airspace enlargement
and destruction of the alveolar wall. In the whey peptide-
based enteral diet group (Fig. 2c), both the airspace
enlargement and destruction of the alveolar wall were
attenuated. The standard enteral diet group (Fig. 2d) did
not suppress the airspace enlargement and destruction of
the alveolar wall. Comparisons of MLI were shown at
Fig. 2e. MLI in the control diet group was significantly in-
creased by elastase instillation (28.7 ± 2.7 μm vs. 53.2 ±
11.4 μm, P = 0.021). The increase was significantly sup-
pressed by the whey peptide-based enteral diet (53.2 ±
11.4 μm vs. 31.9 ± 3.1 μm, P = 0.021) while the increase
was not changed by standard enteral diet.
Whey diet decreased total cell counts in BALF
In the control diet group elastase instillation significantly
increased not only the total cell count (73.8 ± 12.5 × 103
vs. 127.5 ± 29.0 × 103, P = 0.021), but also macrophage
(68.5 ± 12.6 × 103 vs. 116.5 ± 27.1 × 103, P = 0.021), lympho-
cyte (3.69 ± 0.47 × 103 vs. 5.39 ± 1.07 × 103, P = 0.021) and
neutrophil (0.155 ± 0.033 × 103 vs. 0.562 ± 0.236 × 103,
P = 0.021) counts in the BALF (Fig. 3).
The increases in total cell and macrophage count were
significantly suppressed by whey peptide-based enteral
diet (127.5 ± 29.0 × 103 vs. 75.0 ± 12.9× 103, P = 0.021,
116.5 ± 27.1 × 103 vs. 67.8 ± 12.3 × 103, P = 0.021, respect-
ively) while those were not changed by standard enteral
diet (Fig. 3A and B). The increases in lymphocyte and
neutrophil counts were not proved in the whey diet
group (5.39 ± 1.07 × 103 vs. 4.15 ± 0.67 × 103, P = 0.149,
Fig. 1 Changes in body weight in the 4 weeks following elastase
instillation to induce emphysema. Results are expressed as mean ±
standard error of mean. Symbols: , phosphate buffered saline-instilled
mice with control diet (sham; n = 4); , elastase-instilled mice on the
control diet (n = 4); ,elastase-instilled mice on the whey
peptide-based enteral diet (n = 4); , elastase-instilled mice on
the standard enteral diet (n = 4). There were no significant differences
at any weeks before and after elastase instillation between the 4
groups, compared using Mann–Whitney U tests
Fig. 2 Whey peptide suppressed elastase-induced emphysematous changes. Histologically in the control diet groups, elastase-instillation induced
emphysematous lesions with enlargement and disruption of alveolar walls (a and b). These changes were remarkably suppressed by whey peptide
(c), while these were not suppressed by standard enteral diet (d). Changes in mean linear intercept (MLI), one of the morphologic parameters, were
shown at e. In the control diet groups these were enlarged by elastase-instillation. The enlargements were suppressed by the whey peptide, while
those were not suppressed by the standard enteral diet. Results are expressed as mean ± standard deviation of mean and compared using
Mann–Whitney U tests. The sham group consisted of phosphate buffered saline-instilled mice on a control diet
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0.562 ± 0.236 × 103 vs. 0.309 ± 0.220 × 103, P = 0.149, re-
spectively), while those increases were not changed by
standard enteral diet (Fig. 3c and d).
Whey diet increased cecal SCFA levels
In the elastase-instilled mice, the whey peptide-based
enteral diet increased the total cecal SCFA levels
(43.69 ± 9.17 mmol/L vs. 71.69 ± 19.96 mmol/L, P =
0.021) (P < 0.05). However, there was no significant dif-
ference of the content between in the standard enteral
diet and control diet groups (Fig. 4a).
The comparison in acetic acid, propionic acid and bu-
tyric acid in the SCFAs were shown at Fig. 4b, c and d re-
spectively. Whey peptide-based enteral diet increased the
amounts in acetic acid (31.08 ± 8.25 mmol/L vs. 51.27 ±
13.84 mmol/L, P = 0.021) and propionic acid level (6.81 ±
0.88 mmol/L vs. 14.23 ± 5.09 mmol/L, P = 0.021). How-
ever, there was no significant difference in the levels be-
tween the standard enteral diet and control diet groups
(Fig. 4b and c). The butyric acid level in the whey pep-
tide group was significantly higher than that in control
diet group (6.19 ± 1.94 mmol/L vs. 5.80 ± 0.66 mmol/L,
P = 0.021) (Fig. 4d).
Whey Inflammatory cytokine levels in plasma and BALF
In plasma or BALF, TNF-α and IL-6 was not detected in
any animals.
Relationship between total cecal SCFA levels and total
cell count in the BALF from elastase-instilled mice
Total cell count in the BALF from elastase-instilled mice
was inversely correlated with total cecal SCFA levels
(r = 0.596, P = 0.041) (Fig. 5). This result suggested that
whey peptide-based enteral diet accelerated fermenta-
tion by micro-flora in the gut and that the acceleration
may be related to suppression in the increased total cell
counts in BALF.
Discussion
The present study demonstrated that a whey peptide-
based enteral diet suppressed elastase-induced emphy-
sema in mice, compared with both a control diet and a
standard enteral diet. The increase in total cell, neutro-
phil, and lymphocyte counts observed in the lungs of the
mice fed with the control diet was not observed in mice
with the whey peptide-based enteral diet, suggesting that
the resulting anti-inflammatory effect in the lungs may
a b
c d
Fig. 3 Whey peptide suppressed the increase in total cell counts of BALF. In the control diet groups elastase instillation increased total cell
and macrophage counts in the BALF. The increases were significantly suppressed by whey peptide, while these were not suppressed by
standard enteral diet (a and b). In the control diet groups elastase instillation increased lymphocyte and neutrophil counts. The significant
increases were similarly observed in the standard enteral diet group, while the increases were not proved in the whey peptide diet group
(c and d). Results are expressed as mean ± standard deviation of mean and compared using Mann–Whitney U tests. The sham group
consisted of phosphate buffered saline-instilled mice on a control diet
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contribute to the suppression of the elastase-induced
emphysema.
Systemic inflammation is present in COPD [2, 4], and
malnutrition, as one of the systemic effects of COPD, is
an independent prognostic factor of disease outcome.
Various nutritional therapies have been investigated to im-
prove the prognosis of COPD, and a whey peptide-based
enteral diet may suppress the systemic inflammation
present in COPD patients. Previous reports have also
indicated that a whey peptide-based enteral diet is use-
ful for atopic dermatitis, hepatitis, and gut ischemia re-
perfusion injury in animal models [5–8]. This may be
related to the systemic anti-inflammatory effects pro-
vided by the whey peptide-based enteral diet, but this
mechanism is not fully understood. In the current
study, plasma TNF-α, IL-6 were not detected in the
control diet and the whey peptide-based enteral diet
groups, indicating that systemic anti-inflammatory ef-
fects do not necessarily explain changes in the inflam-
matory environment in the lungs.
We inferred from recent epidemiological data demon-
strating beneficial effects of dietary fiber for lung func-
tion and COPD [10–12], together with the importance
of dietary fiber in maintaining the gut environment [13],
and that changes in the gut environment may contribute
to the development of COPD. Intestinal micro-flora pro-
duce organic acids, including SCFA, which confer anti-
inflammatory effects to the host. Our previous results
indicated that cigarette smoke alters cecal organic acid
levels, and a fiber-free diet, combined with cigarette
smoke, decreases the antioxidant capacity related to the
gut acid levels. These results led us to further explore
the effects of intestinal organic acids on inflammation in
other body systems. In this study the use of a whey
a b
c d
Fig. 4 Whey peptide increased short fatty chain acid levels. In elastase-instilled mice whey peptide increased total levels of SCFA (a), acetic acid (b),
propionic acid (c) and butyric acid (d) while the increases were not proved by standard enteral diet. Results are expressed as mean ± standard deviation
of mean and compared using Mann–Whitney U tests. The sham group consisted of phosphate buffered saline-instilled mice on a control diet
Fig. 5 Total cell count in the BALF was inversely correlated with total
cecal SCFA levels. Total cell count in the BALF from elastase-instilled
mice was inversely correlated with total cecal SCFA levels
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peptide-based enteral diet increased the SCFA levels of
the cecum which in turn significantly correlated with
total cell count in the BALF. These results suggest that
an increase in intestinal SCFAs may contribute to anti-
inflammatory processes in the lung. Not only organic
acids but also microflora is crucial in maintaining the
gut environment. Analysis of the proportion of micro-
flora needs to be investigated. Further investigation is
needed to understand the link between the lung and the
gut when consuming a whey peptide-based enteral diet.
Conclusions
A whey peptide-based enteral diet inhibited elastase-
induced emphysema in mice through the suppression of
inflammation in the lungs. This may be related to the in-
crease in cecal SCFAs that was present with the diet.
Therefore, the results from the study suggest that a whey
peptide-based enteral diet may be useful not only for
systemic inflammation but also to slow the progression
of COPD.
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